Header Logo

Connection

WAI CHIN FOO to Humans

Back to Details
This is a "connection" page, showing publications WAI CHIN FOO has written about Humans.
WAI CHIN FOO
Connection Strength
0.140
Humans
  1. A unique presentation of acute liver failure from herpes simplex virus hepatitis. Transpl Infect Dis. 2016 Aug; 18(4):592-4.
    View in: PubMed
    Score: 0.011
  2. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Jun; 44(6):1024-30.
    View in: PubMed
    Score: 0.008
  3. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. J Exp Med. 2024 Oct 07; 221(10).
    View in: PubMed
    Score: 0.005
  4. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis. Breast Cancer Res Treat. 2024 Jun; 205(2):403-411.
    View in: PubMed
    Score: 0.005
  5. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open. 2024 02 05; 7(2):e240260.
    View in: PubMed
    Score: 0.005
  6. Interobserver Variability and Challenges in Intraoperative Frozen Section Evaluation of Pancreatic Margins in Pancreatectomy Specimens. Ann Clin Lab Sci. 2023 Nov; 53(6):847-860.
    View in: PubMed
    Score: 0.004
  7. Treatment Variation and Long-Term Outcomes of Low-Grade Appendiceal Neoplasms. Ann Surg Oncol. 2023 Dec; 30(13):8138-8143.
    View in: PubMed
    Score: 0.004
  8. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open. 2023 06 01; 6(6):e2316161.
    View in: PubMed
    Score: 0.004
  9. Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms. Langenbecks Arch Surg. 2023 Feb 28; 408(1):110.
    View in: PubMed
    Score: 0.004
  10. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 2023 04 20; 41(12):2181-2190.
    View in: PubMed
    Score: 0.004
  11. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
    View in: PubMed
    Score: 0.004
  12. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 02; 75(2):297-308.
    View in: PubMed
    Score: 0.004
  13. Clinical Characteristics and Outcomes of Eosinophilic Colitis in Patients With Cancer. Am J Clin Oncol. 2021 08 01; 44(8):395-401.
    View in: PubMed
    Score: 0.004
  14. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res. 2021 06 01; 27(11):3039-3049.
    View in: PubMed
    Score: 0.004
  15. Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. J Natl Cancer Inst. 2021 02 01; 113(2):208-211.
    View in: PubMed
    Score: 0.004
  16. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg. 2021 Nov; 162(5):1404-1412.e2.
    View in: PubMed
    Score: 0.004
  17. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer. 2020 10; 123(8):1262-1270.
    View in: PubMed
    Score: 0.004
  18. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clin Colorectal Cancer. 2020 09; 19(3):e117-e123.
    View in: PubMed
    Score: 0.003
  19. Neutropenic Enterocolitis: Clinical Features and Outcomes. Dis Colon Rectum. 2020 03; 63(3):381-388.
    View in: PubMed
    Score: 0.003
  20. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Am J Clin Oncol. 2019 10; 42(10):789-796.
    View in: PubMed
    Score: 0.003
  21. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer. 2019 Dec 01; 125(23):4164-4171.
    View in: PubMed
    Score: 0.003
  22. Significance of T1a and T1b Carcinoma Arising in Mucinous Cystic Neoplasm of Pancreas. Am J Surg Pathol. 2018 05; 42(5):578-586.
    View in: PubMed
    Score: 0.003
  23. Lynch Syndrome: Genomics Update and Imaging Review. Radiographics. 2018 Mar-Apr; 38(2):483-499.
    View in: PubMed
    Score: 0.003
  24. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol. 2017 Nov; 24(12):3667-3672.
    View in: PubMed
    Score: 0.003
  25. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Mol Cancer Res. 2017 11; 15(11):1542-1550.
    View in: PubMed
    Score: 0.003
  26. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. Am J Surg Pathol. 2017 Aug; 41(8):1097-1104.
    View in: PubMed
    Score: 0.003
  27. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017 03 14; 18(11):2780-2794.
    View in: PubMed
    Score: 0.003
  28. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453.
    View in: PubMed
    Score: 0.003
  29. A Positive TGF-?/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. Neoplasia. 2016 06; 18(6):371-86.
    View in: PubMed
    Score: 0.003
  30. Deeper Insights Into Vanishing Bile Duct Syndrome in Lymphoma: A Perplexing Entity. Clin Lymphoma Myeloma Leuk. 2016 05; 16(5):e65-70.
    View in: PubMed
    Score: 0.003
  31. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist. 2015 Mar; 20(3):e3-4.
    View in: PubMed
    Score: 0.002
  32. The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nat Med. 2014 Jun; 20(6):596-8.
    View in: PubMed
    Score: 0.002
  33. FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. Histol Histopathol. 2012 05; 27(5):641-9.
    View in: PubMed
    Score: 0.002
  34. Iatrogenic infection of a colonic cystic lymphangioma following cold-forceps biopsy. Endoscopy. 2012; 44 Suppl 2 UCTN:E104-5.
    View in: PubMed
    Score: 0.002
  35. In-depth evaluation of the AJCC/UICC 1997 staging system of nasopharyngeal carcinoma: prognostic homogeneity and proposed refinements. Int J Radiat Oncol Biol Phys. 2003 Jun 01; 56(2):413-26.
    View in: PubMed
    Score: 0.001
  36. Trends in breast cancer incidence in Hong Kong between 1973 and 1999: an age-period-cohort analysis. Br J Cancer. 2002 Oct 21; 87(9):982-8.
    View in: PubMed
    Score: 0.001
  37. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002 Aug; 13(8):1252-8.
    View in: PubMed
    Score: 0.001
  38. Total biological effect on late reactive tissues following reirradiation for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2000 Mar 01; 46(4):865-72.
    View in: PubMed
    Score: 0.001
  39. Staging of nasopharyngeal carcinoma: from Ho's to the new UICC system. Int J Cancer. 1999 Apr 20; 84(2):179-87.
    View in: PubMed
    Score: 0.001
  40. Recurrent nasopharyngeal carcinoma: the puzzles of long latency. Int J Radiat Oncol Biol Phys. 1999 Apr 01; 44(1):149-56.
    View in: PubMed
    Score: 0.001
  41. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998 Jan; 16(1):70-7.
    View in: PubMed
    Score: 0.001
  42. Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys. 1997 Apr 01; 38(1):43-52.
    View in: PubMed
    Score: 0.001
  43. Staging of nasopharyngeal carcinoma: evaluation of N-staging by Ho and UICC/AJCC systems. Union Internationale Contre le Cancer. American Joint Committee for Cancer. Clin Oncol (R Coll Radiol). 1996; 8(3):146-54.
    View in: PubMed
    Score: 0.001
  44. N-staging of nasopharyngeal carcinoma: discrepancy between UICC/AJCC and Ho systems. Union Internationale Contre le Cancer. American Joint Committee for Cancer. Clin Oncol (R Coll Radiol). 1996; 8(3):155-9.
    View in: PubMed
    Score: 0.001
  45. Effect of time, dose and fractionation on local control of nasopharyngeal carcinoma. Radiother Oncol. 1995 Jul; 36(1):24-31.
    View in: PubMed
    Score: 0.001
  46. T1 nasopharyngeal carcinoma: the effect of waiting time on tumor control. Int J Radiat Oncol Biol Phys. 1994 Dec 01; 30(5):1111-7.
    View in: PubMed
    Score: 0.001
  47. Retrospective analysis of patients with nasopharyngeal carcinoma treated during 1976-1985: survival after local recurrence. Int J Radiat Oncol Biol Phys. 1993 Aug 01; 26(5):773-82.
    View in: PubMed
    Score: 0.001
  48. Nasopharyngeal carcinoma: local control by megavoltage irradiation. Br J Radiol. 1993 Jun; 66(786):528-36.
    View in: PubMed
    Score: 0.001
  49. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992; 23(2):261-70.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.